22 May 2017

Bluejay Diagnostics’ Board of Directors Announces Appointment of Douglas C. Wurth as Chairman

Acton, MA – May 22, 2017 – Bluejay Diagnostics, Inc. (Bluejay) today announced that its board of directors unanimously named Douglas C. Wurth as the Company’s chairman, effective immediately. Mr. Wurth recently retired from J.P. Morgan Chase after a successful 19-year career with the Firm, where he was the Chief Executive Officer of Alternative Investments for J.P. Morgan Asset Management. In this role, he led...

Read More

27 Feb 2017

Bluejay Diagnostics, Inc. Announces Clinical Research Collaboration to Development of Care Test for Allergic Conjunctivitis

Collaboration focused on developing non-invasive diagnostic test to identify total IgE in human tears. Acton, MA – February 27, 2017 – Bluejay Diagnostics, Inc. (Bluejay) today announced a collaborative clinical research agreement with Hitachi Chemical Co., Ltd. (Hitachi Chemical) to develop a non-invasive, point-of-care test that measures total IgE in human tears. The technology could be used to aid in the diagnosis of Allergic Conjunctivitis,...

Read More